ADVA
9.12.2021 09:20:09 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced the latest software release of its core and edge timing technology, bringing new levels of PNT security and resilience to synchronization networks. The upgraded series of PTP grandmaster clock solutions now enables operators to automatically harness public key infrastructure. Along with enhanced certificate management, this delivers more robust security and removes complexity. ADVA’s core and mid-sized PTP grandmaster devices now also integrate enhanced aPNT+™ technology , providing advanced jamming and spoofing detection as well as mitigation with automatic switchover in the event of cyberattacks. The software replaces costly hardware devices previously used for PNT protection and achieves enhanced DHS Level 4 Resiliency in PNT self-survivability, the highest in the industry. What’s more, the new software release supports 100Mbit/s over fiber for interconnectivity with optical timing channels from third-part vendors as well as support for PTP profiles for a wide range of industries.
“Today’s timing networks require greater accuracy than ever before. But mission-critical national networks need improved resilience and security as defined by the latest standards. With our trusted PNT assurance solutions, we’re providing the GNSS protection and cybersecurity that today’s operators need to meet current and future challenges,” said Gil Biran, GM of Oscilloquartz, ADVA. “From phase synchronization in critical national infrastructure to traceable timestamping in financial networks, highly precise and protected timing is key to successful operations. This upgrade sets a new standard for secure synchronization and delivers it to more networks than ever before.”
The new 11.1.1 software release features upgrades to ADVA’s comprehensive range of Oscilloquartz edge timing products, the OSA 5412/22 Series, as well as its core synchronization devices, the OSA 5430/40 Series. The solutions now provide multi-layered security for synchronization infrastructure through improved certification management and PKI. As part of ADVA’s intelligent and scalable assured PNT platform, the ADVA aPNT+™ , the solutions also feature innovation for detection of spoofing and jamming as well as countermeasures to prevent service disruption. With PTP capabilities for new verticals, including the PTP broadcast profiles (SMPTE ST-2059-2/AES67), the new release will bring precise, reliable synchronization to many new customers.
The new release follows the four layers of augmented protection as defined in the DHS Resilient PNT Conformance Framework (IEEE P1952 Resilient PNT UE working group). These are: antenna level with a new anti-jamming antenna; GNSS receiver level with single and multi-band options; device level with state-of-the-art anti-jamming and spoofing technology; and network level with sophisticated anti-jamming and anti-spoofing technology based on our Ensemble Controller with Sync Director management suite. Additionally, the device and network levels integrate multi-source backup for diversity and multi-level fault-tolerant mitigation for trusted PNT assurance protection, prevention and recovery.
“In a lot of industries and government networks, failure of network synchronization is no longer an option. It could have devastating consequences for a business’s future or even put lives at risk. That’s why more and more customers are deploying our portfolio of the most advanced and comprehensive aPNT+™ timing technology. As well as ensuring nanosecond accuracy, our enhanced series of PTP grandmasters now provide the most robust defense against cyberattacks,” commented Nir Laufer, VP of product line management at Oscilloquartz, ADVA. “This release extends many of our most powerful features beyond telecom. It opens the door for government, defense, broadcasters, data centers, smart grids and more to take advantage of technologies like our multi-band receivers and AI-power GNSS protection.”
Further information is available in these slides: https://adva.li/apnt-security-enhancements-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005047/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom